MedTrace Logo

Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

NCT00586664 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2013-02-08

Study results available
· View outcomes & findings →

Summary

Efficacy and safety study of bepotastine besilate ophthalmic solution in allergic conjunctivitis

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

Bepreve (bepotastine besilate ophthalmic solution) 1.5%

sterile ophthalmic solution

DRUG

placebo comparator

sterile ophthalmic solution

DRUG

Bepotastine Besilate Ophthalmic Solution 1.0%

sterile ophthalmic solution

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Principal Investigators

  • Tim McNamara, PharmD · ISTA Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00586664 on ClinicalTrials.gov